Find Funding Opportunities

COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements

All NINDS-related funding opportunity announcements (FOAs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed.Search the Closed Announcements tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

Expiration Date: Saturday, April 15, 2023FOA Number: RFA-DE-23-014Release Date: Tuesday, January 10, 2023Announcement Type: RFA

To support planning Grant applications that conceptualize the design and implementation of a future national, interdisciplinary, patient-centered research collaborative that will advance Temporomandibular Disorders (TMDs) basic and clinical research, research training, and translation to evidence-based treatments and improved clinical care. These planning grants are intended to enable the institutions to develop the necessary partnerships, infrastructure, and capabilities needed to address the major goals of the future collaborative, develop collaborative -wide research framework and strategies, and coordinate among studies, research projects, and sites, and thereby enhance competitiveness for future participation in TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT).

Expiration Date: Friday, March 24, 2023FOA Number: RFA-NS-23-012Release Date: Monday, January 9, 2023Announcement Type: RFA
The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.
Expiration Date: Saturday, March 18, 2023FOA Number: RFA-NS-23-002Release Date: Friday, January 6, 2023Announcement Type: RFA
The purpose of this Alzheimers Disease-Related Dementia (ADRD) initiative is to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research with data aimed at understanding the underlying pathophysiology of in vivo imaging results typically associated with vascular contributions to cognitive impairment and dementia (VCID) in TBI-related dementia and other ADRD diagnoses. Resources developed under this FOA must follow open data sharing practices and are intended to expand the broader research communitys capacity to perform research aimed at neuropathologically-informed understanding of the vascular pathophysiology of clinically-relevant, in vivo neuroimaging findings.
Expiration Date: Saturday, October 14, 2023FOA Number: RFA-EB-22-003Release Date: Thursday, January 5, 2023Announcement Type: RFA
This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort. Awards will be integrated into the BRAIN Non-Invasive Imaging Consortium, as a coordinated network on brain function/connectivity imaging.
Research Category: Heal, PainExpiration Date: Saturday, September 6, 2025FOA Number: PAR-23-069Release Date: Tuesday, January 3, 2023Announcement Type: PAR

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects in pain management to the commercialization stage by providing additional assistance for private partnering activities through the Commercialization Readiness Pilot (CRP) program. Specifically, this FOA supports the addition of entrepreneurial expertise into small business leadership teams along with supporting partnering activities to aid in commercialization through private third-party funding or partnership with industry.

Expiration Date: Thursday, March 2, 2023FOA Number: RFA-PM-23-002Release Date: Friday, December 23, 2022Announcement Type: RFA
The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages investigators to apply for grant applications that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Programs Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community. This FOA uses the R03 grant mechanism to support data analysis using standard methods, while the companion FOA (link) uses the R21 mechanism for new tool development and application.
Expiration Date: Thursday, March 2, 2023FOA Number: RFA-PM-23-001Release Date: Friday, December 23, 2022Announcement Type: RFA
The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages investigators to apply for grant applications that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Programs Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community. This FOA uses the R21 grant mechanism for new tool development and application, while the companion FOA (link) uses the R03 grant mechanism to support data analysis using standard methods.
Expiration Date: Tuesday, May 9, 2023FOA Number: PAR-23-079Release Date: Thursday, December 22, 2022Announcement Type: PAR
This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities.Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity.
Expiration Date: Friday, February 16, 2024FOA Number: RFA-MH-23-335Release Date: Thursday, December 22, 2022Announcement Type: RFA
The goal of this effort is to support the development and validation of next generation platforms and analytic approaches to precisely quantify behaviors in humans and link them with simultaneously recorded brain activity. Tools used for analyzing behavior should be multi-modal and should be able to be linked to brain activity and thus have the accuracy, specificity, temporal resolution, and flexibility commensurate with tools used to measure and modulate the brain circuits that give rise to those behaviors. This phased award will support novel tool development (i.e., hardware/software) in the R61 phase and synchronization of novel tools for measuring behavior and human brain activity in the R33 phase.
Expiration Date: Tuesday, May 9, 2023FOA Number: PAR-23-078Release Date: Thursday, December 22, 2022Announcement Type: PAR
This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of community and include semi-automated methods.Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase. Applications that have a significant focus on software and tool development are not appropriate for this activity.